Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 2
2022 1
2023 6
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
DrugMap: A quantitative pan-cancer analysis of cysteine ligandability.
Takahashi M, Chong HB, Zhang S, Lazarov MJ, Harry S, Maynard M, White R, Murrey HE, Hilbert B, Neil JR, Gohar M, Ge M, Zhang J, Durr BR, Kryukov G, Tsou CC, Brooijmans N, Alghali ASO, Rubio K, Vilanueva A, Harrison D, Koglin AS, Ojeda S, Karakyriakou B, Healy A, Assaad J, Makram F, Rachman I, Khandelwal N, Tien PC, Popoola G, Chen N, Vordermark K, Richter M, Patel H, Yang TY, Griesshaber H, Hosp T, van den Ouweland S, Hara T, Bussema L, Dong R, Shi L, Rasmussen MQ, Domingues AC, Lawless A, Fang J, Yoda S, Nguyen LP, Reeves SM, Wakefield FN, Acker A, Clark SE, Dubash T, Fisher DE, Maheswaran S, Haber DA, Boland G, Sade-Feldman M, Jenkins R, Hata A, Bardeesy N, Suva ML, Martin B, Liau B, Ott C, Rivera MN, Lawrence MS, Bar-Peled L. Takahashi M, et al. Among authors: lawless a. bioRxiv [Preprint]. 2023 Oct 23:2023.10.20.563287. doi: 10.1101/2023.10.20.563287. bioRxiv. 2023. PMID: 37961514 Free PMC article. Updated. Preprint.
Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma.
Patrinely JR Jr, Johnson R, Lawless AR, Bhave P, Sawyers A, Dimitrova M, Yeoh HL, Palmeri M, Ye F, Fan R, Davis EJ, Rapisuwon S, Long GV, Haydon A, Osman I, Mehnert JM, Carlino MS, Sullivan RJ, Menzies AM, Johnson DB. Patrinely JR Jr, et al. Among authors: lawless ar. JAMA Oncol. 2021 May 1;7(5):744-748. doi: 10.1001/jamaoncol.2021.0051. JAMA Oncol. 2021. PMID: 33764387 Free PMC article.
Immune Responses in Checkpoint Myocarditis Across Heart, Blood, and Tumor.
Blum SM, Zlotoff DA, Smith NP, Kernin IJ, Ramesh S, Zubiri L, Caplin J, Samanta N, Martin SC, Tirard A, Sen P, Song Y, Barth J, Slowikowski K, Nasrallah M, Tantivit J, Manakongtreecheep K, Arnold BY, McGuire J, Pinto CJ, McLoughlin D, Jackson M, Chan P, Lawless A, Sharova T, Nieman LT, Gainor JF, Juric D, Mino-Kenudsen M, Sullivan RJ, Boland GM, Stone JR, Thomas MF, Neilan TG, Reynolds KL, Villani AC. Blum SM, et al. Among authors: lawless a. bioRxiv [Preprint]. 2023 Nov 29:2023.09.15.557794. doi: 10.1101/2023.09.15.557794. bioRxiv. 2023. PMID: 37790460 Free PMC article. Preprint.
DrugMap: A quantitative pan-cancer analysis of cysteine ligandability.
Takahashi M, Chong HB, Zhang S, Yang TY, Lazarov MJ, Harry S, Maynard M, Hilbert B, White RD, Murrey HE, Tsou CC, Vordermark K, Assaad J, Gohar M, Dürr BR, Richter M, Patel H, Kryukov G, Brooijmans N, Alghali ASO, Rubio K, Villanueva A, Zhang J, Ge M, Makram F, Griesshaber H, Harrison D, Koglin AS, Ojeda S, Karakyriakou B, Healy A, Popoola G, Rachmin I, Khandelwal N, Neil JR, Tien PC, Chen N, Hosp T, van den Ouweland S, Hara T, Bussema L, Dong R, Shi L, Rasmussen MQ, Domingues AC, Lawless A, Fang J, Yoda S, Nguyen LP, Reeves SM, Wakefield FN, Acker A, Clark SE, Dubash T, Kastanos J, Oh E, Fisher DE, Maheswaran S, Haber DA, Boland GM, Sade-Feldman M, Jenkins RW, Hata AN, Bardeesy NM, Suvà ML, Martin BR, Liau BB, Ott CJ, Rivera MN, Lawrence MS, Bar-Peled L. Takahashi M, et al. Among authors: lawless a. Cell. 2024 May 9;187(10):2536-2556.e30. doi: 10.1016/j.cell.2024.03.027. Epub 2024 Apr 22. Cell. 2024. PMID: 38653237
Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy.
Revach OY, Cicerchia AM, Shorer O, Petrova B, Anderson S, Park J, Chen L, Mehta A, Wright SJ, McNamee N, Tal-Mason A, Cattaneo G, Tiwari P, Xie H, Sweere JM, Cheng LC, Sigal N, Enrico E, Miljkovic M, Evans SA, Nguyen N, Whidden ME, Srinivasan R, Spitzer MH, Sun Y, Sharova T, Lawless AR, Michaud WA, Rasmussen MQ, Fang J, Palin CA, Chen F, Wang X, Ferrone CR, Lawrence DP, Sullivan RJ, Liu D, Sachdeva UM, Sen DR, Flaherty KT, Manguso RT, Bod L, Kellis M, Boland GM, Yizhak K, Yang J, Kanarek N, Sade-Feldman M, Hacohen N, Jenkins RW. Revach OY, et al. Among authors: lawless ar. bioRxiv [Preprint]. 2024 Mar 26:2024.02.12.579184. doi: 10.1101/2024.02.12.579184. bioRxiv. 2024. PMID: 38405985 Free PMC article. Preprint.
Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-Risk Resected Melanoma.
Goodman RS, Lawless A, Woodford R, Fa'ak F, Tipirneni A, Patrinely JR, Yeoh HL, Rapisuwon S, Haydon A, Osman I, Mehnert JM, Long GV, Sullivan RJ, Carlino MS, Menzies AM, Johnson DB. Goodman RS, et al. Among authors: lawless a. JAMA Netw Open. 2023 Aug 1;6(8):e2327145. doi: 10.1001/jamanetworkopen.2023.27145. JAMA Netw Open. 2023. PMID: 37535354 Free PMC article.
Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma.
Goodman RS, Di Guardo L, Maurichi A, Kirwin B, Khattak A, Vanella V, Lee J, Lawless A, Czapla J, Spagnoletti A, Ambrosini M, Livingstone E, Long GV, Sullivan RJ, Carlino MS, Atkinson V, Trojanello C, Ascierto PA, Schadendorf D, Warburton L, Menzies AM, Santinami M, Johnson DB. Goodman RS, et al. Among authors: lawless a. Eur J Cancer. 2023 Nov;194:113354. doi: 10.1016/j.ejca.2023.113354. Epub 2023 Sep 22. Eur J Cancer. 2023. PMID: 37827067
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study.
Bai X, Shaheen A, Grieco C, d'Arienzo PD, Mina F, Czapla JA, Lawless AR, Bongiovanni E, Santaniello U, Zappi H, Dulak D, Williamson A, Lee R, Gupta A, Li C, Si L, Ubaldi M, Yamazaki N, Ogata D, Johnson R, Park BC, Jung S, Madonna G, Hochherz J, Umeda Y, Nakamura Y, Gebhardt C, Festino L, Capone M, Ascierto PA, Johnson DB, Lo SN, Long GV, Menzies AM, Namikawa K, Mandala M, Guo J, Lorigan P, Najjar YG, Haydon A, Quaglino P, Boland GM, Sullivan RJ, Furness AJS, Plummer R, Flaherty KT. Bai X, et al. Among authors: lawless ar. EClinicalMedicine. 2023 Oct 31;65:102290. doi: 10.1016/j.eclinm.2023.102290. eCollection 2023 Nov. EClinicalMedicine. 2023. PMID: 37965433 Free PMC article.
14 results